{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:01:38Z","timestamp":1794848498752,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020265","name":"Stan Perron Charitable Foundation","doi-asserted-by":"publisher","award":["00046ProgPart"],"award-info":[{"award-number":["00046ProgPart"]}],"id":[{"id":"10.13039\/501100020265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","award":["00018Research P&P"],"award-info":[{"award-number":["00018Research P&P"]}],"id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024253","name":"Western Australian Future Health and Innovation Fund, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128731","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T21:25:28Z","timestamp":1779571528000},"page":"128731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia"],"prefix":"10.1016","volume":"86","author":[{"given":"Fiona","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128731_bb0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2352-4642(22)00092-X","article-title":"Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis","volume":"6","author":"Pratt","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2026.128731_bb0010","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128731_bb0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40266-024-01118-9","article-title":"Respiratory syncytial virus infection in older adults: an update","volume":"41","author":"Alfano","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2026.128731_bb0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00002512-200522070-00004","article-title":"Respiratory syncytial virus infection in elderly adults","volume":"22","author":"Falsey","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2026.128731_bb0025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0030","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128731_bb0035","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3611","article-title":"Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016","volume":"146","author":"Rha","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128731_bb0040","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1017\/S0950268815003015","article-title":"High burden of RSV hospitalization in very young children: a data linkage study","volume":"144","author":"Homaira","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.vaccine.2026.128731_bb0045","article-title":"Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study","volume":"44","author":"Lassoued","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2026.128731_bb0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJMoa2314885","article-title":"Nirsevimab and hospitalization for RSV bronchiolitis","volume":"391","author":"Assad","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0055","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus\u2013associated hospitalization among infants entering their first respiratory syncytial virus season \u2014 New Vaccine Surveillance Network, october 2023\u2013february 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.vaccine.2026.128731_bb0060","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","author":"L\u00f3pez-Lacort","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128731_bb0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128731_bb0070","article-title":"Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024","volume":"90","author":"Wadia","year":"2025","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.vaccine.2026.128731_bb0075","series-title":"Minister for Health and Aged Care, press conference - 10 November 2024","author":"Australian Government Department of Health, Care A","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128731_bb0080","series-title":"NSW RSV Prevention Program - Information for health professionals","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128731_bb0085","series-title":"Respiratory syncytial virus (RSV) immunisation","author":"Department of Health. Victoria, Australia","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128731_bb0090","series-title":"Vaccination Matters","author":"Department of Health. Queensland","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128731_bb0095","series-title":"RSV maternal and infant protection program 2025","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128731_bb0100","series-title":"Immunisation program","author":"Northern Territory Government","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128731_bb0105","series-title":"ACT Government RSV prevention program - information for health care providers in the ACT","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128731_bb0110","series-title":"2025 WA Respiratory Syncytial Virus (RSV) Infant and Maternal Immunisation Program","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128731_bb0115","series-title":"Australian product information \u2013 abrysvo\u00ae (recombinant respiratory syncytial virus pre-fusion f protein) vaccine","author":"Australian government","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128731_bb0120","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0125","series-title":"Australian immunisation handbook - Respiratory syncytial virus (RSV)","author":"Australian government","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128731_bb0130","series-title":"2025 WA Respiratory Syncytial Virus (RSV) Infant and Maternal Immunisation Program","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128731_bb0135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5694\/mja2.52671","article-title":"Respiratory syncytial virus preventives for children in Australia: current landscape and future directions","volume":"222","author":"Barnett","year":"2025","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.vaccine.2026.128731_bb0140","series-title":"position paper on immunization to protect infants against respiratory syncytial virus disease, May 2025","author":"WHO","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128731_bb0145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12879-024-09400-2","article-title":"Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants","volume":"24","author":"Giannini","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128731_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127155","article-title":"Estimating the impact of Western Australia\u2019s first respiratory syncytial virus immunisation program for all infants: a mathematical modelling study","volume":"56","author":"Giannini","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128731_bb0155","series-title":"Current CDC Vaccine Price List. Vaccines for Children Program","author":"CDC","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128731_bb0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00285-021-01706-y","article-title":"Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review","volume":"84","author":"Lang","year":"2022","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.vaccine.2026.128731_bb0165","article-title":"Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus hospitalisations in early life: a scoping review of dynamic modelling studies","author":"Bicego","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2026.128731_bb0170","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","article-title":"Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis","volume":"18","author":"Hodgson","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0175","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1016\/j.vaccine.2017.09.043","article-title":"Potential impact of a maternal vaccine for RSV: a mathematical modelling study","volume":"35","author":"Hogan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128731_bb0180","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.vaccine.2021.05.100","article-title":"Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand","volume":"39","author":"Prasad","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128731_bb0185","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1093\/infdis\/jiaa424","article-title":"Estimating transmission parameters for respiratory syncytial virus and predicting the impact of maternal and Pediatric vaccination","volume":"222","author":"van Boven","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128731_bb0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.vaccine.2016.10.073","article-title":"Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: a consensus modelling approach","volume":"35","author":"Pan-Ngum","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128731_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2020.100055","article-title":"Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting","volume":"4","author":"Kinyanjui","year":"2020","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128731_bb0200","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2352-4642(24)00143-3","article-title":"Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study","volume":"8","author":"Brault","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2026.128731_bb0205","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-021-00566-9","article-title":"Potential impact of Nirsevimab on RSV transmission and medically attended lower respiratory tract illness caused by RSV: a disease transmission model","volume":"11","author":"Voirin","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.vaccine.2026.128731_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126418","article-title":"Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia","volume":"42","author":"Nazareno","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128731_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41541-022-00550-5","article-title":"Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children","volume":"7","author":"Zheng","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128731_bb0220","article-title":"Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination","volume":"38","author":"Hodgson","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2026.128731_bb0225","first-page":"9","article-title":"Cohort profile: a population-based record linkage platform to address critical epidemiological evidence gaps in respiratory syncytial virus and other respiratory infections","author":"Sarna","year":"2024","journal-title":"IJPDS"},{"key":"10.1016\/j.vaccine.2026.128731_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177803","article-title":"Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya","volume":"12","author":"Nyiro","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128731_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2021-323375","article-title":"Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia","volume":"107","author":"Foley","year":"2022","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.vaccine.2026.128731_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/v16050656","article-title":"The changing detection rate of respiratory syncytial virus in adults in Western Australia between 2017 and 2023","volume":"16","author":"Foley","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128731_bb0245","author":"Census DataPacks"},{"key":"10.1016\/j.vaccine.2026.128731_bb0250","series-title":"conmat: Builds contact matrices using GAMs and population data","author":"Tierney","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128731_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005697","article-title":"Projecting social contact matrices in 152 countries using contact surveys and demographic data","volume":"13","author":"Prem","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.vaccine.2026.128731_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0265","series-title":"Census of population and housing","author":"Census EH","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128731_bb0270","series-title":"Childhood Education and Care, Australia","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128731_bb0275","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128731_bb0280","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2026.128731_bb0285","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0290","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12916-020-01783-8","article-title":"Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting","volume":"18","author":"Campbell","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.vaccine.2026.128731_bb0295","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5694\/mja2.52655","article-title":"Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis","volume":"222","author":"Bloomfield","year":"2025","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.vaccine.2026.128731_bb0300","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-020-02390-5","article-title":"RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.vaccine.2026.128731_bb0305","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/ppul.26324","article-title":"Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants","volume":"58","author":"Stiboy","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.vaccine.2026.128731_bb0310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2431-14-80","article-title":"Morbidity due to acute lower respiratory infection in children with birth defects: a total population-based linked data study","volume":"14","author":"Jama-Alol","year":"2014","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.vaccine.2026.128731_bb0315","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5694\/mja2.51989","article-title":"Influenza and pertussis vaccine coverage in pregnancy in Australia, 2016-2021","volume":"218","author":"McRae","year":"2023","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.vaccine.2026.128731_bb0320","author":"Chemist warehouse"},{"key":"10.1016\/j.vaccine.2026.128731_bb0325","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13052-025-01844-9","article-title":"Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection","volume":"51","author":"Manti","year":"2025","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.vaccine.2026.128731_bb0335","series-title":"Respiratory Syncytial Virus Infection (RSV)","article-title":"RSV Vaccines","author":"CDC","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128731_bb0340","series-title":"National RSV vaccination programme announced","author":"Department of Health, Care S","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128731_bb0345","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2471700","article-title":"Respiratory syncytial virus immunization with nirsevimab: acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain)","volume":"21","author":"Jes\u00fas P\u00e9rez Mart\u00edn","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128731_bb0350","article-title":"RSV vaccine used in 40 other countries could save babies\u2019 lives - doctors","author":"Hill","year":"2025","journal-title":"RNZ"},{"key":"10.1016\/j.vaccine.2026.128731_bb0355","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.003","article-title":"166.A Phase 2b\/3 study to evaluate the efficacy and safety of an investigational Respiratory Syncytial Virus (RSV) antibody, Clesrovimab, in healthy preterm and full-term infants","volume":"12","author":"Zar","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128731_bb0360","article-title":"ACIP recommends Clesrovimab for infants under 8 months without maternal RSV protection","author":"Abene","year":"2025","journal-title":"ContagionLive"},{"key":"10.1016\/j.vaccine.2026.128731_bb0365","series-title":"Advisory Committee on Immunization Practices April 16, 2025","article-title":"Evidence to Recommendations Framework: Clesrovimab","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128731_bb0370","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/apa.17127","article-title":"Parental awareness and attitudes towards prevention of respiratory syncytial virus in infants and young children in Australia","volume":"113","author":"Holland","year":"2024","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.vaccine.2026.128731_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126164","article-title":"Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants","volume":"42","author":"Gebretekle","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128731_bb0380","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.14622","article-title":"Scenario projections of respiratory syncytial virus hospitalizations averted due to new immunizations","volume":"8","author":"Hansen","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.vaccine.2026.128731_bb0385","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12916-025-03928-z","article-title":"Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada","volume":"23","author":"Bugden","year":"2025","journal-title":"BMC Med."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:40:19Z","timestamp":1785249619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"alternative-id":["S0264410X26005402"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128731","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128731"}}